|
1
|
Ajani JA, D'Amico TA, Almhanna K, Bentrem
DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, et al:
National comprehensive cancer network: Esophageal and
esophagogastric junction cancers, version 1.2015. J Natl Compr Canc
Netw. 13:194–227. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fitzmaurice C, Dicker D, Pain A, Hamavid
H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R,
Wolfe C, et al: Global Burden of Disease Cancer Collaboration: The
Global Burden of Cancer 2013. JAMA Oncol. 1:505–527.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
De Angelis R, Sant M, Coleman MP,
Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H,
Ardanaz E, et al: EUROCARE-5 Working Group: Cancer survival in
Europe 1999-2007 by country and age: Results of EUROCARE--5-a
population-based study. Lancet Oncol. 15:23–34. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lagergren J, Smyth E, Cunningham D and
Lagergren P: Oesophageal cancer. Lancet. 390:2383–2396.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kim MI: Surprised by tears. Christ Nurse
Int. 5:6–7. 1989.PubMed/NCBI
|
|
7
|
Grote T, Siwak DR, Fritsche HA, Joy C,
Mills GB, Simeone D, Whitcomb DC and Logsdon CD: Validation of
reverse phase protein array for practical screening of potential
biomarkers in serum and plasma: Accurate detection of CA19-9 levels
in pancreatic cancer. Proteomics. 8:3051–3060. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lee G, Ge B, Huang TK, Zheng G, Duan J and
Wang IH: Positive identification of CA215 pan cancer biomarker from
serum specimens of cancer patients. Cancer Biomark. 6:111–117.
2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lee G, Laflamme E, Chien CH and Ting HH:
Molecular identity of a pan cancer marker, CA215. Cancer Biol Ther.
7:2007–2014. 2008.PubMed/NCBI
|
|
10
|
Zhang S, Wang YM, Sun CD, Lu Y and Wu LQ:
Clinical value of serum CA19-9 levels in evaluating resectability
of pancreatic carcinoma. World J Gastroenterol. 14:3750–3753.
2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC
and Choi KW: Clinical usefulness of carbohydrate antigen 19-9 as a
screening test for pancreatic cancer in an asymptomatic population.
J Gastroenterol Hepatol. 19:182–186. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Singh S, Tang SJ, Sreenarasimhaiah J, Lara
LF and Siddiqui A: The clinical utility and limitations of serum
carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic
cancer and cholangiocarcinoma. Dig Dis Sci. 56:2491–2496.
2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee G: Cancer cell-expressed
immunoglobulins: CA215 as a pan cancer marker and its diagnostic
applications. Cancer Biomark. 5:137–142. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hao Y, Yu Y, Wang L, Yan M, Ji J, Qu Y,
Zhang J, Liu B and Zhu Z: IPO-38 is identified as a novel serum
biomarker of gastric cancer based on clinical proteomics
technology. J Proteome Res. 7:3668–3677. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hardt PD and Ewald N: Tumor M2 pyruvate
kinase: A tumor marker and its clinical application in
gastrointestinal malignancy. Expert Rev Mol Diagn. 8:579–585.
2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gaber A, Johansson M, Stenman UH,
Hotakainen K, Pontén F, Glimelius B, Bjartell A, Jirström K and
Birgisson H: High expression of tumour-associated trypsin inhibitor
correlates with liver metastasis and poor prognosis in colorectal
cancer. Br J Cancer. 100:1540–1548. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Husi H, Stephens N, Cronshaw A, MacDonald
A, Gallagher I, Greig C, Fearon KC and Ross JA: Proteomic analysis
of urinary upper gastrointestinal cancer markers. Proteomics Clin
Appl. 5:289–299. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sofiadis A, Dinets A, Orre LM, Branca RM,
Juhlin CC, Foukakis T, Wallin G, Höög A, Hulchiy M, Zedenius J,
Larsson C and Lehtiö J: Proteomic study of thyroid tumors reveals
frequent up-regulation of the Ca2+ -binding protein
S100A6 in papillary thyroid carcinoma. Thyroid. 20:1067–1076.
2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang XH, Zhang LH, Zhong XY, Xing XF, Liu
YQ, Niu ZJ, Peng Y, Du H, Zhang GG, Hu Y, et al: S100A6
overexpression is associated with poor prognosis and is
epigenetically up-regulated in gastric cancer. Am J Pathol.
177:586–597. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wei BR, Hoover SB, Ross MM, Zhou W, Meani
F, Edwards JB, Spehalski EI, Risinger JI, Alvord WG, Quiñones OA,
et al: Serum S100A6 concentration predicts peritoneal tumor burden
in mice with epithelial ovarian cancer and is associated with
advanced stage in patients. PLoS One. 4(e7670)2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hua Z, Chen J, Sun B, Zhao G, Zhang Y,
Fong Y, Jia Z and Yao L: Specific expression of osteopontin and
S100A6 in hepatocellular carcinoma. Surgery. 149:783–791.
2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Komatsu K, Andoh A, Ishiguro S, Suzuki N,
Hunai H, Kobune-Fujiwara Y, Kameyama M, Miyoshi J, Akedo H and
Nakamura H: Increased expression of S100A6 (calcyclin), a
calcium-binding protein of the S100 family, in human colorectal
adenocarcinomas. Clin Cancer Res. 6:172–177. 2000.PubMed/NCBI
|
|
23
|
Sanders ME, Dias EC, Xu BJ, Mobley JA,
Billheimer D, Roder H, Grigorieva J, Dowsett M, Arteaga CL and
Caprioli RM: Differentiating proteomic biomarkers in breast cancer
by laser capture microdissection and MALDI MS. J Proteome Res.
7:1500–1507. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Loos M, Bergmann F, Bauer A, Hoheisel JD,
Esposito I, Kleeff J, Schirmacher P, Büchler MW, Klöppel G and
Friess H: Solid type clear cell carcinoma of the pancreas:
differential diagnosis of an unusual case and review of the
literature. Virchows Archiv. 450:719–726. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Fry LC, Mönkemüller K and Malfertheiner P:
Molecular markers of pancreatic cancer: Development and clinical
relevance. Langenbecks Arch Surg. 393:883–890. 2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ljungberg B: Prognostic markers in renal
cell carcinoma. Curr Opin Urol. 17:303–308. 2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Higgins JP: Gene array studies in renal
neoplasia. ScientificWorldJournal. 6:502–511. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang J, Chen J and Sen S: MicroRNA as
Biomarkers and Diagnostics. J Cell Physiol. 231:25–30.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lindner K, Haier J, Wang Z, Watson DI,
Hussey DJ and Hummel R: Circulating microRNAs: emerging biomarkers
for diagnosis and prognosis in patients with gastrointestinal
cancers. Clin Sci (Lond). 128:1–15. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Schultz NA, Dehlendorff C, Jensen BV,
Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE,
Yilmaz M, Holländer NH, et al: MicroRNA biomarkers in whole blood
for detection of pancreatic cancer. JAMA. 311:392–404.
2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bosco C, Wulaningsih W, Melvin J,
Santaolalla A, De Piano M, Arthur R and Van Hemelrijck M: Metabolic
serum biomarkers for the prediction of cancer: A follow-up of the
studies conducted in the Swedish AMORIS study.
Ecancermedicalscience. 9(555)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Xie G, Lu L, Qiu Y, Ni Q, Zhang W, Gao YT,
Risch HA, Yu H and Jia W: Plasma metabolite biomarkers for the
detection of pancreatic cancer. J Proteome Res. 14:1195–1202.
2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hirata Y, Kobayashi T, Nishiumi S,
Yamanaka K, Nakagawa T, Fujigaki S, Iemoto T, Kobayashi M, Okusaka
T, Nakamori S, et al: Identification of highly sensitive biomarkers
that can aid the early detection of pancreatic cancer using
GC/MS/MS-based targeted metabolomics. Clin Chim Acta. 468:98–104.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Husi H, Skipworth RJ, Cronshaw A, Fearon
KC and Ross JA: Proteomic identification of potential cancer
markers in human urine using subtractive analysis. Int J Oncol.
48:1921–1932. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kalantari S, Jafari A, Moradpoor R,
Ghasemi E and Khalkhal E: Human Urine Proteomics: Analytical
Techniques and Clinical Applications in Renal Diseases. Int J
Proteomics. 2015(782798)2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wu J, Chen YD and Gu W: Urinary proteomics
as a novel tool for biomarker discovery in kidney diseases. J
Zhejiang Univ Sci B. 11:227–237. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Husi H, Ward MA, Choudhary JS, Blackstock
WP and Grant SG: Proteomic analysis of NMDA receptor-adhesion
protein signaling complexes. Nat Neurosci. 3:661–669.
2000.PubMed/NCBI View
Article : Google Scholar
|
|
38
|
Brand RE, Nolen BM, Zeh HJ Allen PJ,
Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD,
Vickers SM, et al: Serum biomarker panels for the detection of
pancreatic cancer. Clin Cancer Research. 17:805–816.
2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Nolen BM, Brand RE, Prosser D,
Velikokhatnaya L, Allen PJ, Zeh HJ, Grizzle WE, Huang Y, Lomakin A
and Lokshin AE: Prediagnostic serum biomarkers as early detection
tools for pancreatic cancer in a large prospective cohort study.
PLoS One. 9(e94928)2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Caffrey RE: A review of experimental
design best practices for proteomics based biomarker discovery:
Focus on SELDI-TOF. Methods Mol Biol. 641:167–183. 2010.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Okamoto A, Yamamoto H, Imai A, Hatakeyama
S, Iwabuchi I, Yoneyama T, Hashimoto Y, Koie T, Kamimura N, Mori K,
et al: Protein profiling of post-prostatic massage urine specimens
by surface-enhanced laser desorption/ionization time-of-flight mass
spectrometry to discriminate between prostate cancer and benign
lesions. Oncol Rep. 21:73–79. 2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Gagnon A, Shi Q and Ye B: Surface-enhanced
laser desorption/ionization mass spectrometry for protein and
Peptide profiling of body fluids. Methods Mol Biol. 441:41–56.
2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhang Y, Li Y, Qiu F and Qiu Z:
Comparative analysis of the human urinary proteome by 1D SDS-PAGE
and chip-HPLC-MS/MS identification of the AACT putative urinary
biomarker. J Chromatogr B Analyt Technol Biomed Life Sci.
878:3395–3401. 2010.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rubin H, Wang ZM, Nickbarg EB, McLarney S,
Naidoo N, Schoenberger OL, Johnson JL and Cooperman BS: Cloning,
expression, purification, and biological activity of recombinant
native and variant human alpha 1-antichymotrypsins. J Biol Chem.
265:1199–1207. 1990.PubMed/NCBI
|
|
45
|
Pinczower GD, Williams RP, Gianello RD,
Robinson HC, Preston BN and Linnane AW: Characterisation of the
tumour-associated carbohydrate epitope recognised by monoclonal
antibody 4D3. Int J Cancer. 66:636–644. 1996.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Koomen JM, Shih LN, Coombes KR, Li D, Xiao
LC, Fidler IJ, Abbruzzese JL and Kobayashi R: Plasma protein
profiling for diagnosis of pancreatic cancer reveals the presence
of host response proteins. Clin Cancer Res. 11:1110–1118.
2005.PubMed/NCBI
|
|
47
|
Yu KH, Rustgi AK and Blair IA:
Characterization of proteins in human pancreatic cancer serum using
differential gel electrophoresis and tandem mass spectrometry. J
Proteome Res. 4:1742–1751. 2005.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Roberts AS, Campa MJ, Gottlin EB, Jiang C,
Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM and Patz
EF Jr: Identification of potential prognostic biomarkers in
patients with untreated, advanced pancreatic cancer from a phase 3
trial (Cancer and Leukemia Group B 80303). Cancer. 118:571–578.
2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Niedergethmann M, Wostbrock B, Sturm JW,
Willeke F, Post S and Hildenbrand R: Prognostic impact of cysteine
proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
Pancreas. 29:204–211. 2004.PubMed/NCBI
|
|
50
|
Hosokawa M, Kashiwaya K, Eguchi H,
Ohigashi H, Ishikawa O, Furihata M, Shinomura Y, Imai K, Nakamura Y
and Nakagawa H: Over-expression of cysteine proteinase inhibitor
cystatin 6 promotes pancreatic cancer growth. Cancer Sci.
99:1626–1632. 2008.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wu Y, Pan S, Che S, He G, Nelman-Gonzalez
M, Weil MM and Kuang J: Overexpression of Hp95 induces G1 phase
arrest in confluent HeLa cells. Differentiation. 67:139–153.
2001.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Huang ZY, Xiong G, Zhang J and Wang WJ:
[Screening of differentially expressed proteins from human
esophageal cancer and esophageal tissues by two-dimensional
difference gel electrophoresis and mass spectrometry]. Nan Fang Yi
Ke Da Xue Xue Bao. 27:1406–1409. 2007.(In Chinese). PubMed/NCBI
|
|
53
|
Hamaguchi T, Iizuka N, Tsunedomi R,
Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima
M, Tamesa T and Oka M: Glycolysis module activated by
hypoxia-inducible factor 1alpha is related to the aggressive
phenotype of hepatocellular carcinoma. Int J Oncol. 33:725–731.
2008.PubMed/NCBI View Article : Google Scholar
|
|
54
|
van den Broek I, Sparidans RW, Schellens
JH and Beijnen JH: Quantitative assay for six potential breast
cancer biomarker peptides in human serum by liquid chromatography
coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol
Biomed Life Sci. 878:590–602. 2010.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hack CE, Nuijens JH, Felt-Bersma RJ,
Schreuder WO, Eerenberg-Belmer AJ, Paardekooper J, Bronsveld W and
Thijs LG: Elevated plasma levels of the anaphylatoxins C3a and C4a
are associated with a fatal outcome in sepsis. Am J Med. 86:20–26.
1989.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Hassan MI, Aijaz A and Ahmad F: Structural
and functional analysis of human prostatic acid phosphatase. Expert
Rev Anticancer Ther. 10:1055–1068. 2010.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Miyasaki KT and Bodeau AL: Human
neutrophil azurocidin synergizes with leukocyte elastase and
cathepsin G in the killing of Capnocytophaga sputigena. Infect
Immun. 60:4973–4975. 1992.PubMed/NCBI
|
|
58
|
Grønborg M, Bunkenborg J, Kristiansen TZ,
Jensen ON, Yeo CJ, Hruban RH, Maitra A, Goggins MG and Pandey A:
Comprehensive proteomic analysis of human pancreatic juice. J
Proteome Res. 3:1042–1055. 2004.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Sancho M, Diani E, Beato M and Jordan A:
Depletion of human histone H1 variants uncovers specific roles in
gene expression and cell growth. PLoS Genet.
4(e1000227)2008.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zong WX: Histone, H1.2: Another
housekeeping protein that kills. Cancer Biol Ther. 3:42–43.
2004.PubMed/NCBI
|
|
61
|
Chen S, Dong H, Yang S and Guo H:
Cathepsins in digestive cancers. Oncotarget. 8:41690–41700.
2017.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Aggarwal N and Sloane BF: Cathepsin B:
Multiple roles in cancer. Proteomics Clin Appl. 8:427–437.
2014.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Gondi CS and Rao JS: Cathepsin B as a
cancer target. Expert Opin Ther Targets. 17:281–291.
2013.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Madhavan B, Yue S, Galli U, Rana S, Gross
W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW and Zöller
M: Combined evaluation of a panel of protein and miRNA
serum-exosome biomarkers for pancreatic cancer diagnosis increases
sensitivity and specificity. Int J Cancer. 136:2616–2627.
2015.PubMed/NCBI View Article : Google Scholar
|
